New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
16:20 EDTGHDXGenomic Health sees 2H net losses similar to 1H
"Our first half net loss reflects planned investments in the international and prostate cancer markets," said Brad Cole, COO and CFO of Genomic Health. "We anticipate planned investments in DCIS, prostate and international markets to continue through the end of the year, resulting in second half net losses similar to the first half."
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
08:05 EDTGHDXGenomic Health announces positive results for validation study of Oncotype DX
Genomic Health announced strongly positive results from an additional independent clinical validation study of the Oncotype DX prostate cancer test. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen following surgery. In meeting these two endpoints, the Oncotype DX prostate cancer test provides both clinically actionable and long-term outcomes information for men with newly diagnosed low- and intermediate-risk prostate cancer. Furthermore, the study demonstrated that Oncotype DX is similarly predictive of outcomes in both Caucasian and African-American men. The Oncotype DX GPS was also significantly predictive of metastatic prostate cancer recurrence, a notable finding given the likelihood of metastases in patients with low- and intermediate-risk prostate cancer is so small.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use